As cancers and Mtb infection share similar metabolic profiles (Shi et al., 2015; Gleeson et al., 2016), embracing an approach based on immunometabolic assessment will be crucial to develop future therapeutics which incorporate the inhibitors of Akt/mTOR signaling pathway, a major metabolic regulator (Covarrubias et al., 2015), into anti-mycobacterial activity evaluation. The gene discussed is AKT1; the disease is cancer.